AR029199A1 - Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas - Google Patents

Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas

Info

Publication number
AR029199A1
AR029199A1 ARP000106398A ARP000106398A AR029199A1 AR 029199 A1 AR029199 A1 AR 029199A1 AR P000106398 A ARP000106398 A AR P000106398A AR P000106398 A ARP000106398 A AR P000106398A AR 029199 A1 AR029199 A1 AR 029199A1
Authority
AR
Argentina
Prior art keywords
partial
pharmaceutical compositions
derivatives
adenosina
heterociclico
Prior art date
Application number
ARP000106398A
Other languages
English (en)
Spanish (es)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of AR029199A1 publication Critical patent/AR029199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP000106398A 1999-12-03 2000-12-01 Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas AR029199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
AR029199A1 true AR029199A1 (es) 2003-06-18

Family

ID=23803455

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106398A AR029199A1 (es) 1999-12-03 2000-12-01 Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas

Country Status (25)

Country Link
US (2) US6605597B1 (https=)
EP (1) EP1233973B1 (https=)
JP (1) JP4021195B2 (https=)
KR (1) KR100484988B1 (https=)
CN (1) CN1152042C (https=)
AR (1) AR029199A1 (https=)
AT (1) ATE254133T1 (https=)
AU (3) AU4138701A (https=)
BR (1) BR0016126A (https=)
CA (1) CA2389264C (https=)
CZ (1) CZ20013705A3 (https=)
DE (1) DE60006576T2 (https=)
DK (1) DK1233973T3 (https=)
ES (1) ES2208437T3 (https=)
HK (1) HK1047941A1 (https=)
HU (1) HUP0500455A2 (https=)
IL (1) IL145903A (https=)
MX (1) MXPA01011113A (https=)
NO (1) NO20015373L (https=)
NZ (1) NZ514777A (https=)
PT (1) PT1233973E (https=)
TR (2) TR200103129T2 (https=)
TW (1) TWI249536B (https=)
WO (2) WO2001040243A2 (https=)
ZA (1) ZA200204380B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
JP2005527502A (ja) * 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体の部分的および全アゴニスト
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
JP2007514647A (ja) 2003-10-21 2007-06-07 インスパイアー ファーマシューティカルズ，インコーポレイティド テトラヒドロ−フロ［３，４−ｄ］ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
KR20070083714A (ko) 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 아데노신 수용체 작용제의 용도
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
EP2274007B1 (en) 2008-03-10 2016-12-14 Cornell University Modulation of blood brain barrier permeability
WO2009128934A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995033726A1 (en) * 1994-06-09 1995-12-14 Ss Pharmaceutical Co., Ltd. 4-quinolinone derivative or salt thereof
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives

Also Published As

Publication number Publication date
WO2001040243A3 (en) 2001-12-13
WO2001040243A2 (en) 2001-06-07
US6605597B1 (en) 2003-08-12
EP1233973A1 (en) 2002-08-28
NZ514777A (en) 2004-01-30
CA2389264C (en) 2007-03-06
CZ20013705A3 (cs) 2002-04-17
DK1233973T3 (da) 2004-02-16
NO20015373L (no) 2001-11-29
MXPA01011113A (es) 2002-06-04
WO2001040246A1 (en) 2001-06-07
AU7938301A (en) 2002-03-21
TR200103129T2 (tr) 2002-10-21
CA2389264A1 (en) 2001-06-07
BR0016126A (pt) 2002-08-06
KR100484988B1 (ko) 2005-04-22
AU761029B2 (en) 2003-05-29
TR200301971T4 (tr) 2004-01-21
ES2208437T3 (es) 2004-06-16
PT1233973E (pt) 2004-02-27
JP4021195B2 (ja) 2007-12-12
ZA200204380B (en) 2003-06-25
AU4138701A (en) 2001-06-12
IL145903A (en) 2006-04-10
CN1378550A (zh) 2002-11-06
ATE254133T1 (de) 2003-11-15
JP2003516325A (ja) 2003-05-13
EP1233973B1 (en) 2003-11-12
KR20030032907A (ko) 2003-04-26
DE60006576T2 (de) 2004-09-16
DE60006576D1 (de) 2003-12-18
HUP0500455A2 (hu) 2005-08-29
CN1152042C (zh) 2004-06-02
US20050054605A1 (en) 2005-03-10
AU1811701A (en) 2001-06-12
NO20015373D0 (no) 2001-11-02
HK1047941A1 (zh) 2003-03-14
TWI249536B (en) 2006-02-21

Similar Documents

Publication Publication Date Title
AR029199A1 (es) Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas
AR029198A1 (es) Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
ECSP003713A (es) Derivados de purina
ECSP003712A (es) Derivados de la purina
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ECSP941122A (es) Derivados de 5-arilindoles
ECSP003531A (es) Derivados de purina
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
BR0207952A (pt) Moduladores da atividade de receptores de quimiocina
ATE187726T1 (de) A1 adenosin rezeptor agonisten und antagonisten
GT199900008A (es) Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
UY30783A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticos
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
BRPI0814529B8 (pt) derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas de alfa2c para uso no tratamento de doenças do sistema nervoso periférico e central
DE60318219D1 (de) PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
DE69626705D1 (de) A1 adenosin rezeptor agonisten und antagonisten
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as

Legal Events

Date Code Title Description
FB Suspension of granting procedure